Type 2 diabetes mellitus with diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Intervention 1: Intervention group: Q10 capsule 100mg / once-daily for 8 weeks, manufacture of HEALTH Burst america pharmaceutical company. Intervention 2: Control group: placebo capsule once-dai
Treatment - Drugs
Placebo
Intervention group: Q10 capsule 100mg / once-daily for 8 weeks, manufacture of HEALTH Burst america pharmaceutical company
Control group: placebo capsule once-daily for 8 weeks,manufacture of Osweh Iran pharmaceutical company
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: type 2 diabetes normoalbuminuria or microalbuminuria
Exclusion criteria
Exclusion criteria: macroalbuminuria type 1 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteinuria base on randomly Albumin/ cratinine ratio. Timepoint: before intervention and every 6 months to 18 months later. Method of measurement: base on randomly urine Albumin/ cratinine ratio. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean of fasting blood suger. Timepoint: before intervention and every 6 months to 18 months later. Method of measurement: lab test.;Percentage of Glycosylated hemoglobin. Timepoint: before intervention and every 6 months to 18. Method of measurement: lab test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahman Sadeghi
Arak University of Medical Sciences
Outcome results
None listed